{
  "id": 1699914,
  "title": "Jasper Therapeutics stock rating reiterated at Buy by H.C. Wainwright",
  "url": "https://urgent.news/2026/08/18/jasper-therapeutics-stock-rating-reiterated-at-buy-by-h-c-wainwright",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-18T11:37:02.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/jasper-therapeutics-stock-rating-reiterated-at-buy-by-hc-wainwright-93CH-4864947"
  },
  "original_language": "en",
  "account": "H.C. Wainwright has maintained a positive outlook on Jasper Therapeutics, maintaining a Buy rating and raising its price target to $20.00. The stock is currently trading at $0.84, down 71% over the past year. Jasper Therapeutics' earnings report and corporate update, released on Friday, followed the company's acquisition of Kira Pharmaceuticals in July. The update indicated that legacy Jasper equity holders own approximately 6.68% of the combined company, while former Kira equity holders own around 49.86%, and private placement investors own about 43.46%. Jasper has raised $132 million in a private placement and separately out-licensed two products to Mirador Therapeutics. The company's pro-forma cash funds operations through the second half of fiscal 2028 and covers data for KP-104, expected in the fourth quarter of fiscal 2026. The Fair Value analysis suggests the stock may be undervalued, but the company is burning through cash quickly. Jasper Therapeutics is set to have key meetings with the FDA and plans to submit an investigational new drug filing for KP-701 in the first quarter of fiscal 2027. Despite earning higher-than-expected results, Jasper's shares declined in pre-market trading.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}